Immediate Impact
1 from Science/Nature 63 standout
Citing Papers
Pancreatic cancer
2025 Standout
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
2025 Standout
Works of Swantje Held being referenced
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
2019
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Swantje Held | 877 | 422 | 263 | 310 | 81 | 1.1k | |
| Jen‐Kou Lin | 649 | 250 | 186 | 268 | 50 | 1.1k | |
| Stacey Stein | 780 | 377 | 342 | 164 | 74 | 1.4k | |
| Regina Esser | 899 | 463 | 195 | 334 | 39 | 1.1k | |
| Silvia Mezi | 983 | 398 | 215 | 283 | 50 | 1.3k | |
| Julian Walter Holch | 795 | 339 | 200 | 345 | 48 | 1.1k | |
| Mehmet Akce | 799 | 238 | 145 | 184 | 110 | 1.1k | |
| Andrew Strickland | 867 | 423 | 208 | 271 | 31 | 1.0k | |
| Lucio Giustini | 864 | 401 | 113 | 286 | 41 | 1.3k | |
| Bum Jun Kim | 522 | 442 | 274 | 147 | 61 | 1.1k | |
| Janja Ocvirk | 996 | 372 | 221 | 176 | 68 | 1.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...